Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M36,506Revenue $M2,234Net Margin (%)29.4Z-Score26.5
Enterprise Value $M34,709EPS $3.3Operating Margin %38.9F-Score8
P/E(ttm))55.4Cash Flow Per Share $0.8Pre-tax Margin (%)39.0Higher ROA y-yY
Price/Book10.910-y EBITDA Growth Rate %0Quick Ratio4.3Cash flow > EarningsN
Price/Sales16.35-y EBITDA Growth Rate %52.3Current Ratio4.6Lower Leverage y-yY
Price/Cash Flow115y-y EBITDA Growth Rate %63.8ROA % (ttm)17.9Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)22.8Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M202ROI % (ttm)16.0Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNAndreas Halvorsen 2014-12-31 Reduce-1.23%$159.46 - $200.79
($185.68)
$ 180.59-3%Reduce -82.25%390,271
ALXNJoel Greenblatt 2014-12-31 Add0.13%$159.46 - $200.79
($185.68)
$ 180.59-3%Add 4665.74%85,974
ALXNRay Dalio 2014-12-31 Buy 0.03%$159.46 - $200.79
($185.54)
$ 180.59-3%New holding18,513
ALXNAndreas Halvorsen 2014-09-30 Add0.13%$155.06 - $173.08
($164.22)
$ 180.599%Add 9.59%2,198,451
ALXNJoel Greenblatt 2014-09-30 Reduce-0.03%$155.06 - $173.08
($164.22)
$ 180.599%Reduce -89.45%1,804
ALXNRay Dalio 2014-09-30 Sold Out -0.03%$155.06 - $173.08
($164.22)
$ 180.599%Sold Out0
ALXNAndreas Halvorsen 2014-06-30 Add0.12%$139.61 - $170.2
($157.93)
$ 180.5913%Add 9.23%2,006,092
ALXNRay Dalio 2014-06-30 Reduce-0.03%$139.61 - $170.2
($157.93)
$ 180.5913%Reduce -47.72%26,332
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 180.5913%Add 240.11%17,094
ALXNJohn Burbank 2014-06-30 Sold Out -0.01%$139.61 - $170.2
($157.93)
$ 180.5913%Sold Out0
ALXNFrank Sands 2014-03-31 Reduce-0.74%$129.82 - $183.89
($158.27)
$ 180.5912%Reduce -28.52%5,268,418
ALXNAndreas Halvorsen 2014-03-31 Reduce-0.65%$129.82 - $183.89
($158.27)
$ 180.5912%Reduce -36.16%1,836,658
ALXNRay Dalio 2014-03-31 Buy 0.06%$129.82 - $183.89
($158.27)
$ 180.5912%New holding50,371
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 180.5912%New holding5,026
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 180.5912%New holding10,218
ALXNJohn Burbank 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 180.5912%New holding1,318
ALXNAndreas Halvorsen 2013-12-31 Reduce-0.37%$105.48 - $132.91
($119.84)
$ 180.5934%Reduce -16.72%2,877,008
ALXNAndreas Halvorsen 2013-09-30 Reduce-1.06%$94.34 - $117.28
($109.83)
$ 180.5939%Reduce -37.70%3,454,640
ALXNFrank Sands 2013-09-30 Reduce-0.27%$94.34 - $117.28
($109.83)
$ 180.5939%Reduce -10.50%7,540,405
ALXNAndreas Halvorsen 2013-06-30 Reduce-2.15%$87.99 - $107.86
($96.37)
$ 180.5947%Reduce -41.40%5,544,949
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BELL LEONARDCEO 2015-03-19Sell15,952$188.07-6.4view
Sinha VikasEVP & CFO 2015-03-02Sell487$180.34-2.38view
O'Neill JulieEVP. Global Operations 2015-03-02Sell11,665$101.4973.46view
MACKAY MARTINEVP & Global Head of R&D 2015-03-02Sell370$180.34-2.38view
Moriarty John BEVP & General Counsel 2015-03-02Sell280$180.34-2.38view
Islam SaqibEVP, Chief Strat & Port. Off. 2015-03-02Sell228$180.34-2.38view
Carmichael ClareEVP, Chief HR Officer 2015-03-02Sell706$180.34-2.38view
Hallal DavidCOO 2015-03-02Sell730$180.34-2.38view
BELL LEONARDCEO 2015-03-02Sell1,230$180.34-2.38view
Sinha VikasEVP & CFO 2015-02-10Sell1,985$171.152.86view

Press Releases about ALXN :

    Quarterly/Annual Reports about ALXN:

    News about ALXN:

    Articles On GuruFocus.com
    Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
    Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
    Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
    CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
    Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
    Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
    Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 10 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Six High-Impact Sells - Viking Global Investors Aug 27 2013 
    CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 

    More From Our Partners
    Stock Market News for March 26, 2015 - Market News Mar 26 2015 - ZACKS

    More From Other Websites
    ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 26 2015
    Cincinnati Children’s inks deal with Shire to develop drugs Mar 26 2015
    Biotech Stock Selloff: Is It Justified? Mar 26 2015
    The Biotech Selloff: It's Déjà Vu All Over Again Mar 26 2015
    The Best Of The Best: Don't Miss These Top 9 Stocks Mar 25 2015
    Two Healthcare Stocks Provide Antidotes To Wild Market Swings Mar 24 2015
    Learn The ABC's Of 3 Top-Ranked Biotech Stocks Mar 20 2015
    Give Gilead Credit for Surge in Biotech Margins Mar 20 2015
    How the Weaker Euro Is Impacting Biotech Earnings Mar 18 2015
    Why These Could Be 2015's 10-Best Pharma Stocks Mar 17 2015
    ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 16 2015
    Analyst Sees Upside To Outlook At 4 Biotechs Mar 13 2015
    Affymetrix Hits 52-Week High on Stellar Q4, Positive Outlook - Analyst Blog Mar 13 2015
    Analyst: Alexion Pharmaceuticals Pipeline Is Undervalued Mar 11 2015
    Biotech pros’ top 8 stock picks Mar 09 2015
    New Data from First Natural History Study in Juveniles with Hypophosphatasia (HPP) Showing... Mar 07 2015
    New Data from First Natural History Study in Juveniles with Hypophosphatasia (HPP) Showing... Mar 07 2015
    FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Mar 02 2015
    FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Mar 02 2015
    Alexion Joins Patient Organizations Worldwide in Support of International Rare Disease Day 2015 Mar 01 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK